Early findings were shared this week by University of Rochester Medical Center cardiologist John Bisognano, M.D., Ph.D., and Minneapolis-based device-maker CVRx at the American Heart Association 2006 Scientific Sessions in Chicago.
The ongoing study is assessing the safety and clinical efficacy of the RheosTM Baroreflex Hypertension TherapyTM System, an implantable device for the treatment of hypertension in patients with drug-resistant hypertension, who have a systolic blood pressure of 160 mmHg or greater. The University of Rochester implanted the first device in the U.S. in March 2005, and performed a total of three of the initial 10 implantations.
Hypertension affects about 65 million people in the U.S. It is estimated to cause one in every eight deaths worldwide. Each increase of 20 mmHg in systolic blood pressure or 10 mmHg in diastolic blood pressure above normal level is associated with a two-fold increase in death rates from stroke, coronary heart disease and other vascular causes. Approximately 25 percent of people with hypertension cannot control their high blood pressure, despite the use of multiple medications.
"The Rheos System is a novel device that activates the carotid baroreflex, the body's own system for regulating blood pressure," Bisognano said. "We are pleased with the clinical results to date and look forward to expanding the clinical evaluation of the Rheos System. New approaches to the widespread, chronic and costly problem of hypertension are needed. The Rheos System has the potential to prevent the progression to more serious illnesses, including heart and kidney disease, stroke and death."
The system works by electrically activating the baroreflex system based in the carotid arteries in the neck. Low-level electrical stimulation to this area sends signals to the brain, "telling" it to take action to lower blood pressure through a variety of mechanisms, including blood vessel dilatation, heart rate reduction and promotion of fluid excretion by the kidneys. In this way, the system provides a physiologic approach to reducing high blood pressure by allowing the brain to direct the body's own control mechanisms. It consists of a battery-powered implantable generator, which is inserted under the skin near the collarbone, and two carotid sinus leads, which run from the generator to the left and right carotid sinus in the neck. While implantation is slightly more involved, the general principle is similar to the implantation of cardiac pacemakers.
The trial is designed to assess device safety and efficacy in patients with systolic blood pressure of 160 mmHg or greater, despite being on at least three anti-hypertension medications, including one diuretic. The presentation reported on the first 10 U.S. patients enrolled in the trial. After one month of surgical recovery, baseline blood pressure was assessed and the device was activated. Three months of active Rheos therapy reduced systolic blood pressure by an average of 22 mmHg (180 mmHg vs. 158 mmHg) and diastolic blood pressure by an average of 18 mmHg (105 mmHg vs. 87 mmHg), using office cuff measurements. The implants were well tolerated and there were no unanticipated serious adverse events related to the system or procedure.
In October, CVRx received a conditional investigational device exemption (IDE) approval from the U.S. Food and Drug Administration to begin a pivotal clinical trial that will evaluate the safety and effectiveness of the RheosTM Baroreflex Hypertension TherapyTM System in a much larger number of patients. The University of Rochester team recently implanted a fourth device as part of the study.
"These interim clinical results are favorable and promising for the many people with drug-resistant hypertension," said Nadim Yared, president and CEO of CVRx. "We are excited about launching our pivotal trial and look forward to working with our investigators."
Karin Christensen | EurekAlert!
Novel PET imaging method could track and guide therapy for type 1 diabetes
03.08.2018 | Society of Nuclear Medicine and Molecular Imaging
A first look at interstitial fluid flow in the brain
05.07.2018 | American Institute of Physics
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur
What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...
The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.
Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...
If certain signaling cascades are misregulated, diseases like cancer, obesity and diabetes may occur. A mechanism recently discovered by scientists at the Leibniz- Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin and at the University of Geneva has a crucial influence on such signaling cascades and may be an important key for the future development of therapies against these diseases. The results of the study have just been published in the prestigious scientific journal 'Molecular Cell'.
Cell growth and cell differentiation as well as the release and efficacy of hormones such as insulin depend on the presence of lipids. Lipids are small...
08.08.2018 | Event News
27.07.2018 | Event News
25.07.2018 | Event News
13.08.2018 | Physics and Astronomy
13.08.2018 | Physics and Astronomy
13.08.2018 | Physics and Astronomy